These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 33669698)
61. Comprehensive multigene mutation spectra of breast cancer patients from Northeast China obtained using the Ion Torrent sequencing platform. Fan C; Liu N; Fan S; Yang Z; Ye N; Wang K Oncol Rep; 2019 Oct; 42(4):1580-1588. PubMed ID: 31364747 [TBL] [Abstract][Full Text] [Related]
62. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN. Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796 [TBL] [Abstract][Full Text] [Related]
63. The effect of LKB1 on the PI3K/Akt pathway activation in association with PTEN and PIK3CA in HNC. Ekizoglu S; Dogan S; Ulker D; Seven D; Gozen ED; Karaman E; Buyru N Clin Otolaryngol; 2015 Dec; 40(6):622-8. PubMed ID: 25850957 [TBL] [Abstract][Full Text] [Related]
64. Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development. El-Habr EA; Levidou G; Trigka EA; Sakalidou J; Piperi C; Chatziandreou I; Spyropoulou A; Soldatos R; Tomara G; Petraki K; Samaras V; Zisakis A; Varsos V; Vrettakos G; Boviatsis E; Patsouris E; Saetta AA; Korkolopoulou P Virchows Arch; 2014 Oct; 465(4):473-85. PubMed ID: 25146167 [TBL] [Abstract][Full Text] [Related]
65. The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features. Salaün H; Djerroudi L; Haik L; Schnitzler A; Bataillon G; Deniziaut G; Bièche I; Vincent-Salomon A; Debled M; Cottu P J Pathol Clin Res; 2024 May; 10(3):e12372. PubMed ID: 38563252 [TBL] [Abstract][Full Text] [Related]
66. LHX6 inhibits the proliferation, invasion and migration of breast cancer cells by modulating the PI3K/Akt/mTOR signaling pathway. Bi QJ; Men XJ; Han R; Li GL Eur Rev Med Pharmacol Sci; 2018 May; 22(10):3067-3073. PubMed ID: 29863252 [TBL] [Abstract][Full Text] [Related]
67. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors. Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M Cells; 2020 Sep; 9(9):. PubMed ID: 32962206 [TBL] [Abstract][Full Text] [Related]
68. A novel deleterious PTEN mutation in a patient with early-onset bilateral breast cancer. Pradella LM; Evangelisti C; Ligorio C; Ceccarelli C; Neri I; Zuntini R; Amato LB; Ferrari S; Martelli AM; Gasparre G; Turchetti D BMC Cancer; 2014 Feb; 14():70. PubMed ID: 24498881 [TBL] [Abstract][Full Text] [Related]
69. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Chen L; Yang L; Yao L; Kuang XY; Zuo WJ; Li S; Qiao F; Liu YR; Cao ZG; Zhou SL; Zhou XY; Yang WT; Shi JX; Huang W; Hu X; Shao ZM Nat Commun; 2018 Apr; 9(1):1357. PubMed ID: 29636477 [TBL] [Abstract][Full Text] [Related]
70. 3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K/AKT/mTOR signaling pathway. Zhang L; Zheng Y; Zeng L; Zhang F; Che D; Cao Z; Huang C; Xian L; Zhang X; Zhang H; Guo Z Life Sci; 2021 Nov; 285():119995. PubMed ID: 34592228 [TBL] [Abstract][Full Text] [Related]
71. The associations of hub gene polymorphisms in PI3K/AKT/mTOR pathway and Schistosomiasis Japonica infection and hepatic fibrosis. Xiao Q; Yu H; Zhu X Infect Genet Evol; 2020 Nov; 85():104423. PubMed ID: 32554084 [TBL] [Abstract][Full Text] [Related]
72. Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway. Wang LL; Huang WW; Huang J; Huang RF; Li NN; Hong Y; Chen ML; Wu F; Liu J Kaohsiung J Med Sci; 2020 Aug; 36(8):581-591. PubMed ID: 32311203 [TBL] [Abstract][Full Text] [Related]
73. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway. Li YJ; Wang Y; Wang YY J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801 [TBL] [Abstract][Full Text] [Related]
74. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Slomovitz BM; Coleman RL Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003 [TBL] [Abstract][Full Text] [Related]
75. Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway. Liu H; Li X; Duan Y; Xie JB; Piao XL J Ethnopharmacol; 2021 May; 271():113907. PubMed ID: 33556477 [TBL] [Abstract][Full Text] [Related]
76. Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer. Stella S; Vitale SR; Massimino M; Motta G; Longhitano C; Lanzafame K; Martorana F; Fazzari C; Vecchio GM; Tirrò E; Inzerilli N; Carciotto R; Manzella L; Caruso M; Vigneri P Cancer Genomics Proteomics; 2022; 19(4):464-476. PubMed ID: 35732329 [TBL] [Abstract][Full Text] [Related]
77. The prognostic and predictive values of differential expression of exosomal receptor tyrosine kinases and associated with the PI3K/AKT/mTOR signaling in breast cancer patients undergoing neoadjuvant chemotherapy. Guney Eskiler G; Kazan N; Haciefendi A; Deveci Ozkan A; Ozdemir K; Ozen M; Kocer HB; Yilmaz F; Kaleli S; Sahin E; Bilir C Clin Transl Oncol; 2023 Feb; 25(2):460-472. PubMed ID: 36181664 [TBL] [Abstract][Full Text] [Related]
78. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Davis NM; Sokolosky M; Stadelman K; Abrams SL; Libra M; Candido S; Nicoletti F; Polesel J; Maestro R; D'Assoro A; Drobot L; Rakus D; Gizak A; Laidler P; Dulińska-Litewka J; Basecke J; Mijatovic S; Maksimovic-Ivanic D; Montalto G; Cervello M; Fitzgerald TL; Demidenko Z; Martelli AM; Cocco L; Steelman LS; McCubrey JA Oncotarget; 2014 Jul; 5(13):4603-50. PubMed ID: 25051360 [TBL] [Abstract][Full Text] [Related]
79. A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Zhang Y; Kwok-Shing Ng P; Kucherlapati M; Chen F; Liu Y; Tsang YH; de Velasco G; Jeong KJ; Akbani R; Hadjipanayis A; Pantazi A; Bristow CA; Lee E; Mahadeshwar HS; Tang J; Zhang J; Yang L; Seth S; Lee S; Ren X; Song X; Sun H; Seidman J; Luquette LJ; Xi R; Chin L; Protopopov A; Westbrook TF; Shelley CS; Choueiri TK; Ittmann M; Van Waes C; Weinstein JN; Liang H; Henske EP; Godwin AK; Park PJ; Kucherlapati R; Scott KL; Mills GB; Kwiatkowski DJ; Creighton CJ Cancer Cell; 2017 Jun; 31(6):820-832.e3. PubMed ID: 28528867 [TBL] [Abstract][Full Text] [Related]
80. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Wheler JJ; Moulder SL; Naing A; Janku F; Piha-Paul SA; Falchook GS; Zinner R; Tsimberidou AM; Fu S; Hong DS; Atkins JT; Yelensky R; Stephens PJ; Kurzrock R Oncotarget; 2014 May; 5(10):3029-38. PubMed ID: 24912489 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]